Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XAV-19 in Moderate to Severe COVID-19
NCT04928430Phase 3Terminated
- Sponsor
- Xenothera
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of xav-19 in coronavirus disease 2019 (COVID-19), sponsored by Xenothera. Started Apr 2021; status: terminated.
02
Drugs
xav-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04928430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928430.